Summit facilitated cross-collaboration among physicians and surgeons exploring advances in patient care using cryopreserved amniotic membrane allografts

Miami, FL – September 14, 2021 – TissueTech, Inc., a pioneer in the clinical application of cryopreserved amniotic membrane birth tissue allografts, announced today that the company had completed its first physician leadership summit. Beyond the Horizon 2021 was hosted by TissueTech co-founder and Chief Technology Officer Scheffer Tseng, MD, Ph.D. It was held on August 13, 2021, through August 15, 2021, in Dallas, TX. It represented the first time twenty-three ophthalmologists, optometrists, and podiatrists came together in a TissueTech-sponsored leadership summit for practicing healthcare professionals.

TissueTech faculty and noted key opinion leaders Marguerite McDonald, MD, Patti Barkey, COE, Neel Desai, MD, Alan Block, DPM, MS, FACFAS, Thomas Fusco, DPM, FACFAS, and Marissa Carter, Ph.D., MA, MAPWCA conducted presentations throughout the three-day event. These included Practice Economics of Various Ocular Restoration and Surface Optimization Techniques, An Analysis of the Wound Healing Landscape Using Human Birth Tissue to Orchestrate Regenerative Healing, and The Principle of TissueTuck Technique™ for Pterygium. Luminaries and faculty members also led wet lab demonstrations, 3D surgical training sessions, and virtual reality surgical simulations to improve surgical competency. In a study conducted at the David Geffen School of Medicine at the University of California Los Angeles, virtual reality simulation training enables young surgeons to gain valuable experience in a safe environment while boosting surgical competency by as much as 230%.1

Summit attendees included physicians, surgeons, and clinicians from all stages of their careers, and it was evident that collaboration among these multi-specialists was a highlight of the Summit. “Cross-team conversations were met with enthusiasm and proved to be very insightful as many of our summit attendees typically have little opportunity to collaborate in this manner,” said Dr. Tseng. “We found that our leadership summit served as a powerful catalyst to align clinical leaders, address unmet patient needs, introduce new strategies, and fuel collaboration across the regenerative medical spectrum of ocular surface disease and wound care.”

Summit attendees welcomed the opportunity to share best practices with colleagues practicing in specialties other than their own, as evidenced in this statement from summit participant Ken Nguyen, DPM. “I would recommend that future leadership summits continue to give participants exposure to other specialties, applications, and cases from different practitioners across the country that we previously may not have thought would be helpful, but they were. It does change the way you think about wounds and also reconstruction techniques during surgery.”

In addition to fostering innovation in regenerative medicine, TissueTech is also committed to innovating healthcare cost containment. A 2018 retrospective analysis of Medicare beneficiaries identified that ∼8.2 million people had wounds with or without infections; Medicare cost estimates for acute and chronic wound treatments ranged from $28.1 billion to $96.8 billion a year. The highest expenses were for surgical wounds followed by diabetic foot ulcers. Increasing healthcare costs, an aging population, and the continued threat of diabetes and obesity worldwide make chronic wounds a substantial clinical, social, and economic challenge. In contrast, direct and indirect costs associated with eye disorders and vision loss total $139 billion per year, according to research commissioned by Prevent Blindness America (PBA). This amount puts eye disorders ahead of hypertension, diabetes, and stroke direct costs. 2,3

About TissueTech, Inc.

TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with its products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://tissuetech.com.

About Amniox Medical, Inc.

Amniox Medical, Inc. is a TissueTech, Inc. company. It is focused on harnessing the unique power of human birth tissue to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications. The Amniox family of cryopreserved amniotic membrane products are processed using its proprietary CRYOTEK® technology to retain the birth tissue’s structural and functional integrity. Amniox is committed to facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives. Connect with Amniox on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.

About Bio-Tissue, Inc.

Bio-Tissue, Inc. is a TissueTech, Inc. company. It is pioneering the clinical application of human birth tissue to promote regenerative healing for ocular surface disease and disorders. The Bio-Tissue portfolio of cryopreserved amniotic membrane products are processed using its proprietary CRYOTEK® technology to retain the birth tissue’s structural and functional integrity. As a leader in clinical research, Bio-Tissue has been facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives since 1997. Connect with Bio-Tissue on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.

  1. Performing a surgical procedure on a virtual patient enables them to try a newly acquired technique or refresh dormant skills. As MD+DI reported in August 2019, a previous Osso VR validation study from August 2019 conducted by the David Geffen School of Medicine at the University of California Los Angeles showed a 230% improvement in the participants’ overall surgical performance when prepared with the company’s VR training.1
  2. https://doi.org/10.1089/wound.2019.0946
  3. https://www.ophthalmologytimes.com/view/report-eye-disorders-cost-139-billion-year